Tvardi at Chardan healthcare conference: new data lifts stat3 hopes

On Tuesday, October 20th, 2026, Tvardi Therapeutics (CARA) highlighted a challenging year for its pharmaceutical pipeline during Chardan's 10th Annual Healthcare Conference. The company showcased promising results in its STAT3 drug strategy, bolstered by fresh mechanistic data, while also addressing setbacks in lung disease research. Tvardi's STAT3-centric approach focuses on non-covalent inhibitors, designed to maintain the protein's normal functions without causing mitochondrial toxicity.

During the conference, Tvardi showcased promising data from an idiopathic pulmonary fibrosis study, revealing a significant reduction in IL-6 levels and a minor decrease in fibrosis among trial participants. The company is advancing its next-generation prodrug, TTI-109, into a phase 2 trial targeting ulcerative colitis, after positive results from healthy volunteer studies.

TTI-101, the company's first-generation molecule, continues to be pursued in hepatocellular carcinoma trials, with three distinct development paths outlined, including potential accelerated approval for third-line monotherapy.

In terms of safety, Tvardi's approach to STAT3 inhibition has shown no mitochondrial toxicity events in over 400 trial subjects treated with TTI-101 and TTI-109. Despite a setback in the idiopathic pulmonary fibrosis study, the company reported generating $38.9 million in revenue over the past year, with an 83% gross profit margin.

However, the company is actively managing its cash reserves as it pushes forward with multiple clinical programs, maintaining a strong financial health score of 3.25 and a market capitalization of $186 million.